Koss Olinger Consulting LLC Sells 252 Shares of Johnson & Johnson $JNJ

Koss Olinger Consulting LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,565 shares of the company’s stock after selling 252 shares during the period. Koss Olinger Consulting LLC’s holdings in Johnson & Johnson were worth $1,003,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $218,000. Motiv8 Investments LLC increased its stake in shares of Johnson & Johnson by 6.6% during the first quarter. Motiv8 Investments LLC now owns 9,164 shares of the company’s stock valued at $1,520,000 after purchasing an additional 564 shares in the last quarter. PDS Planning Inc increased its stake in shares of Johnson & Johnson by 9.3% during the first quarter. PDS Planning Inc now owns 18,586 shares of the company’s stock valued at $3,082,000 after purchasing an additional 1,589 shares in the last quarter. Finally, Perpetual Ltd grew its holdings in shares of Johnson & Johnson by 27.2% during the first quarter. Perpetual Ltd now owns 41,288 shares of the company’s stock valued at $6,847,000 after buying an additional 8,830 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. Bank of America increased their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. Raymond James Financial increased their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Argus set a $210.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 15th. Finally, Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 1.1%

Shares of JNJ stock opened at $190.38 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $182.26 and its 200 day moving average is $166.37. The stock has a market capitalization of $458.69 billion, a P/E ratio of 18.38, a P/E/G ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.